DDInter596 DDInter1925
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Doxorubicin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Doxorubicin {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Doxorubicin {u} (Compound) downregulates {v} (Gene) NFIL3
NFIL3 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Doxorubicin {u} (Compound) downregulates {v} (Gene) PPRC1
PPRC1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Doxorubicin {u} (Compound) upregulates {v} (Gene) S100A13
S100A13 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Doxorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) CBR3
CBR3 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Doxorubicin {u} (Compound) causes {v} (Side Effect) Eosinophilia
Eosinophilia {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Doxorubicin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Doxorubicin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) regulates {v} (Gene) FAM63A
FAM63A {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Doxorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Doxorubicin (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Vemurafenib (Compound)
Doxorubicin (Compound) downregulates NFIL3 (Gene) and NFIL3 (Gene) is upregulated by Vemurafenib (Compound)
Doxorubicin (Compound) downregulates PPRC1 (Gene) and PPRC1 (Gene) is downregulated by Vemurafenib (Compound)
Doxorubicin (Compound) upregulates S100A13 (Gene) and S100A13 (Gene) is downregulated by Vemurafenib (Compound)
Doxorubicin (Compound) binds CBR3 (Gene) and Doxorubicin (Compound) downregulates CBR3 (Gene) and CBR3 (Gene) is downregulated by Vemurafenib (Compound)
Doxorubicin (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafenib (Compound)
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may lead to a major life threatening interaction when taken with Vemurafenib
Doxorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Doxorubicin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) regulates FAM63A (Gene) and FAM63A (Gene) is upregulated by Vemurafenib (Compound)